Exhibit 2

State of California ex. rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Laboratories, Inc., et al.

Exhibit to the Declaration of Nicholas N. Paul in Support of Plaintiffs' Motion for Summary Judgment as to Defendant Mylan

```
Page 1
            CAUSE NO. D-1-GV-07-001259
THE STATE OF TEXAS
                              ) IN THE DISTRICT COURT
ex rel.
        VEN-A-CARE OF THE
        FLORIDA KEYS, INC.
        Plaintiffs,
                              )TRAVIS COUNTY, TEXAS
        VS.
SANDOZ, INC. f/k/a GENEVA
PHARMACEUTICALS, INC., EON
LABS,
MYLAN PHARMACEUTICALS, INC., )
MYLAN LABORATORIES, INC.,
UDL LABORATORIES, INC.,
TEVA PHARMACEUTICALS USA,
INC. f/k/a LEMMON
PHARMACEUTICALS, INC., COPLEY)
PHARMACEUTICALS, INC. IVAX )
PHARMACEUTICALS, INC., SICOR )
PHARMACEUTICALS, INC., and )
TEVA NOVOPHARM, INC.,
                              )201st JUDICIAL
         Defendants.
                              ) DISTRICT
      VIDEOTAPE DEPOSITION OF: ERIC BELLDINA
```

```
Page 3
                UNITED STATES DISTRICT COURT
               FOR THE DISTRICT OF MASSACHUSETTS
 2
 3
                                          ) MDL No. 1456
     IN RE: PHARMACEUTICAL INDUSTRY
                                         ) Master File No.
     AVERAGE WHOLESALE PRICE LITIGATION )01-12257-PBS
                                         ) Judge Patti B.
     THIS DOCUMENT RELATES TO:
     State of California, ex rel.
                                         )Saris
     Ven-A-Care v. Abbott Laboratories, )
     Inc., et al.
     Case No. 03-cv-11226-PBS
10
11
12
13
           VIDEOTAPE DEPOSITION OF: ERIC BELLDINA
14
15
16
                      DATE: November 21, 2008
                              Friday, 9:00 a.m.
17
18
                  LOCATION: Lakeview Golf Resort & Spa
                              1 Lakeview Drive
19
                              Morgantown, WV 26508
20
                  TAKEN BY: State of Texas
21
22
               REPORTED BY: JoAnn M. Brown, RMR, CRR
                              Notary Public
23
                              Reference No. JB10033
24
25
```

		Page 49
1	Α.	Yes, we are.
2	Q.	It lists Red Book, First DataBank, Medi-Span
3		and Orange Book?
4	Α.	Yes, that's correct.
5	Q.	And what are those?
6	Α.	Red Book, First DataBank, and Medi-Span are
7		first-party databases that Mylan reported new
8		product information to.
9	Q.	And is that part of your job responsibilities?
10	Α.	Yes, it was.
11	Q.	And what would you report to them?
12	Α.	Approval letters, date of launch, product AWP,
13		product WAC, if necessary, package sizes,
14		color, shape.
15	Q.	So, you would report AWP figures to those
16		service companies?
17	Α.	Yes, I reported AWP figures.
18	Q.	And you knew those price reporting services
19		would publish the numbers you provided to them
20		with regards to the AWP figures?
21		MR. PALERMO: Objection to the form.
22	Α.	Yes, that was my understanding.
23	Q.	As well as any WAC figures that you may have
24		submitted to them?
25		MR. PALERMO: Objection to the form.

Page 161 If the states reimburse off AWP, they would Α. need that information --Q. Okay. -- to list the product. Α. 5 All right. So, if a manufacturer grossly Q. inflated its AWP, would that somehow affect 7 Medicaid reimbursement and the spread for the customers? MR. PALERMO: Objection to the form. 10 Not that I'm aware of. Α. 11 A grossly-inflated AWP would not affect the Q. 12 spread? 13 MR. PALERMO: Objection to the form. 14 Not that I'm aware of. 15 Okay. Do you know if Mylan did this with Q. 16 other Medicaid programs as well, that is, just 17 send AWP page only? 18 MR. PALERMO: Objection to the form. 19 We only reported to four states, New Jersey, Α. 20 Illinois, Texas and Virginia. Everyone else 21 pulled their data from First DataBank, Medi-22 Span or Red Book, unless they had other 23 sources. 24 Mm-hmm. What about Texas? Q. 25 MR. PALERMO: Objection to the form.